[1]隆绍平,邓世群,赵世元.PTPN12蛋白表达下调与原发性肝细胞癌患者复发和预后关系研究[J].现代检验医学杂志,2018,33(01):86-90.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　LONG Shao-ping,DENG Shi-qun,ZHAO Shi-yuan.Association between Downregulation of PTPN12 Protein and Recurrence and Prognosis in Patients with Primary Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(01):86-90.[doi:10.3969/j.issn.1671-7414.2018.01.001]
点击复制

PTPN12蛋白表达下调与原发性肝细胞癌患者复发和预后关系研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年01期
页码:
86-90
栏目:
论著
出版日期:
2018-02-05

文章信息/Info

Title:
Association between Downregulation of PTPN12 Protein and Recurrence and Prognosis in Patients with Primary Hepatocellular Carcinoma
文章编号:
1671-7414(2018)01-086-05
作者:
隆绍平1; 邓世群2; 赵世元3
1.广西百色市人民医院检验科,广西百色 533000; 2.南宁市西乡塘区石埠卫生院检验科,南宁 530008; 3.广西医科大学附属民族医院检验科,南宁 530001
Author(s):
LONG Shao-ping1; DENG Shi-qun2; ZHAO Shi-yuan3
1.Department of Clinical Laboratory, Baise People's Hospital of Guangxi,Guangxi Baise 530000,China; 2.Department of Clinical Laboratory,Nanning Xixiangtang District Shibu Hospital,Nanning530008,China; 3.Department of Clinical Laboratory,the Affiliated National Hospital of Guangxi Medical University,Nanning 530001,China
关键词:
肝细胞癌;  非受体蛋白酪氨酸磷酸酶12蛋白;  预后
分类号:
R735.7; R730.43
DOI:
10.3969/j.issn.1671-7414.2018.01.001
文献标志码:
A
摘要:
目的 探讨非受体蛋白酪氨酸磷酸酶12(PTPN12)在肝癌组织与其癌旁组织中的表达并研究其表达与原发性肝细胞癌预后的关系。方法 以肝癌组织与其癌旁组织为研究对象,用免疫组化法检测肝癌组织及癌旁肝组织的PTPN12蛋白的表达。用等级相关和Cox比例风险回归模型等评估PTPN12蛋白的表达与原发性肝细胞癌预后的关系。结果 与癌旁肝组织相比,在肝癌组织中的PTPN12蛋白表达明显下调(55.83% vs.43.12%,P<0.005)。进一步的相关分析表明PTPN12蛋白表达降低与肿瘤复发密切相关(χ2=4.346,P=0.015); 单因素分析结果表明肝癌PTPN12表达降低与肝癌肿瘤特异生存率和肝癌复发相关(χ2=5.687,P<0.001); 多变量Cox比例风险回归模型分析发现PTPN12表达是肝癌患者预后的独立因素(χ2=6.687,P<0.05)。结论 PTPN12蛋白在人肝癌组织中表达下降或缺失,PTPN12表达可能作为肝细胞癌患者复发和预后的生物标志物。
Abstract:
Abstract:Objective To investigate the expression of nonreceptor protein tyrosine phosphatase 12(PTPN12)in hepatocellular carcinoma(HCC)and its adjacent tissues and investigate the relationship between the expression of non receptor protein and prognosis of hepatocellular carcinoma(HCC).Methods The expresson of PTPN12 protein in HCC tissuesand adjacent liver tissues was detected by immunohistochemistry.The relationship between the expression of PTPN12 protein and prognosis of primary hepatocellular carcinoma was evaluated by rank correlation and Cox proportional hazards regression model.Results Compared with the adjacent liver tissues,the expression of PTPN12 protein in HCC tissues was significantly lower(55.83% vs 43.12%,P<0.005).Further analysis showed that the decreased expression of PTPN12 was closely related with tumor recurrence(χ2=4.346,P=0.015).Single factor analysis showed that the decreased expression of PTPN12 in hepatocellular carcinoma and liver cancer specific survival and recurrenceof hepatocellular carcinoma related(χ2=5.687,P<0.001),and multivariate Cox proportional hazards regression model analysis showed that the expressionof PTPN12 in patients with liver cancer were independent prognostic factors(χ2=6.687,P<0.05).Conclusion The expression of PTPN12 protein was down or absent in human hepatocellular carcinoma,and the expression of PTPN12 may be a biomarker for the recurrence and prognosis of HCC patients.

参考文献/References:

[1] Cai MY,Tong ZT,Zheng F,et al.EZH2 protein:a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies[J].Gut,2011,60(7):967-976.
[2] Yuen MF,Cheng CC,Lauder IJ,et al.Early detection of hepatocellular carcinoma increases the chance of treatment:Hong Kong experience[J].Hepatology,2000,31(2):330-335.
[3] Bruix J,Sherman M,Practice Guidelines Committee,American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma[J].Hepatology,2005,42(5):1208-1236.
[4] Altekruse SF,McGlynn KA,Reichman ME.Hepatocellular carcinoma incidence,mortality,and survival trends in the United States from 1975 to 2005[J].JClin Oncol,2005,27(9):1485-1491.
[5] Hunter T.Tyrosine phosphorylation:thirty years and counting[J].CurrOpin Cell Biol,2009,21(2):140-146.
[6] Yarden Y,Sliwkowski MX.Untangling the ErbB signalling network[J].NatRev Mol Cell Biol,2001,2(2):127-137.
[7] Hsu JL,Huang SY,Chow NH,et al.Stable-isotope dimethyl labeling for quantitative proteomics[J].Anal Chem,2003,75(24):6843-6852.
[8] Sun T,Aceto N,Meerbrey KL,et al.(2011)Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase[J].Cell,144(5):703-718.
[9] 郑耿龙,麦瑞琴,郑高哲,等.PTPN12在乳腺癌中的表达及其影响指标研究[J].中国医药导报,2017,14(5):90-93. Zheng GL,Mai RQ,Zheng GZ,et,al.Study of the expression of PTPN12 in the patients with breast cancer and its influenec indexes[J].China Medical Herald,2017,14(5):90-93.
[10] 阮瑞扬,陈修荣,赵世元.抗EZH2自身抗体IgG在肝癌患者血清中的表达及意义[J].现代检验医学杂志,2017,32(2):72-74. Ruan RY,Chen XR,Zhao SY.Expression and significance of anti EZH2 autoantibody IgG in hepatocellular carcinoma patients serum samples[J].Journal of Modern Laboratory Medicine,2017,32(2):72-74.
[11] 张利云,付丽萍,徐 娟,等.自身抗体在肝癌诊断中的意义[J].现代检验医学杂志,2006,21(2):70-72. Zhang LY,Fu LP,Xu J,et al.Significance of auto-antibody in diagnosisof liver disease[J].Journal of Modern Laboratory Medicine,2006,21(2):70-72.
[12] Yamamoto J,Kosuge T,Takayama T,et al.Recurrence of hepatocellular carcinoma after surgery[J].Br J Surg,1996,83(9):1219-1222.
[13] Lee JS,Heo J,Libbrecht L,et al.A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells[J].Nat Med,2006,12(4):410-416.
[14] Moradpour D,Wands JR.The molecular pathogenesis of hepatocellular carcinoma[J].J Viral Hepat,1994,1(1):17-31.
[15] Tabor E.Tumor suppressor genes,growth factor ge-nes,and oncogenes inhepatitis B virus-associated hepatocellular carcinoma[J].J Med Virol,1994,42(4):357-365.
[16] Hui AM,Makuuchi M,Li X.Cell cycle regulators and human hepatocarcinogenesis[J].Hepatogastroenterology,1998,45(23):1635-1642. 收稿日期:2017-09-28 修回日期:2017-11-20

相似文献/References:

[1]邓旭,王晓亮.肝细胞癌患者血清趋化因子CXCR12和SA的表达及临床意义[J].现代检验医学杂志,2015,30(06):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
　DENG Xu,WANG Xiao-liang.Expression and Clinical Significance of Serum CXCR12 and SA in Patients with Hepatocarcinoma[J].Journal of Modern Laboratory Medicine,2015,30(01):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
[2]毛丽萍,何义民,韩 刚,等.血浆Dickkopf同源物1检测对肝细胞癌的诊断价值[J].现代检验医学杂志,2016,31(05):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
　MAO Li-ping,HE Yi-min,HAN Gang,et al.Diagnosis Value of Detecting Plasma Dickkopf-1 Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(01):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
[3]阮瑞杨,陈修荣,赵世元.抗EZH2自身抗体IgG在肝癌患者血清中的表达及意义[J].现代检验医学杂志,2017,32(02):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
　RUAN Rui-yang,CHEN Xiu-rong,ZHAO Shi-yuan.Expression and Significance of Anti EZH2 Autoantibodies IgG in Hepatocellular Carcinoma Patient's Serum Samples[J].Journal of Modern Laboratory Medicine,2017,32(01):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
[4]毛丽萍,王跃国,王 健,等.CMIA法测定血清DCP与AFP对肝细胞癌的诊断价值[J].现代检验医学杂志,2018,33(06):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
　MAO Li-ping,WANG Yue-guo,WANG Jian,et al.Diagnostic Value of the Serum DCP and AFP Determined by CMIA in Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(01):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
[5]吴良银a,李文丽b,刘 俊a.肝细胞癌患者生存预后相关长链非编码RNA(LncRNA)的生物信息学分析[J].现代检验医学杂志,2019,34(04):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
　WU Liang-yina,LI Wen-lib,LIU Juna.Bioinformatics Analysis of Long-Chain Non-Coding RNA Related to Survival and Prognosis in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2019,34(01):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
[6]吴良银a,李文丽b,刘　俊b.基于GEO数据的病毒相关性肝癌潜在生物基因标志物的筛选及生物信息学分析[J].现代检验医学杂志,2021,36(06):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
　WU Liang-yin,LI Wen-li,LIU Jun.Screening and Bioinformatics Analysis of Potential Biomarkers for Virus-associated Hepatocellular Carcinoma Based on GEO Data[J].Journal of Modern Laboratory Medicine,2021,36(01):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
[7]陈 偲,李忠辉a,王 颖b.miR-198 通过靶向ZEB2 调控EMT 过程抑制肝癌细胞增殖和迁移的机制研究[J].现代检验医学杂志,2022,37(04):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
　CHEN Si,LI Zhong-huia,WANG Yingb.Study on the Mechanism of miR-198 Inhibiting the Proliferation and Migration of Hepatoma Cells by Regulating EMT Process by Targeting ZEB2[J].Journal of Modern Laboratory Medicine,2022,37(01):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
[8]王 路,叶 莎,韩 霞,等.循环外泌体miRNA 检测对肝细胞癌临床诊断效能的Meta 分析[J].现代检验医学杂志,2022,37(04):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
　WANG Lu,YE Sha,HAN Xia,et al.Meta-Analysis of the Diagnostic Value of Circulating Exosomes miRNA Detection for Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(01):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
[9]时晓晓a,董 翔a,于若卉b,等.miR-203a-3p 靶向GLS1 调控HCC 细胞增殖、迁移、侵袭的机制研究[J].现代检验医学杂志,2022,37(05):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]
　SHI Xiao-xiaoa,DONG Xianga,YU Ruo-huib,et al.Mechanism of miR-203a-3p Targeting GLS1 to Regulate the Proliferation, Migration and Invasion of HCC Cells[J].Journal of Modern Laboratory Medicine,2022,37(01):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]
[10]吴翠婷,周雪辉,张婉馨.基于生物学信息分析筛选晚期肝细胞癌患者接受PD-1 抑制剂治疗后糖酵解相关基因差异表达并构建生存获益模型与验证[J].现代检验医学杂志,2023,38(05):34.[doi:10.3969/j.issn.1671-7414.2023.05.007]
　WU Cuiting,ZHOU Xuehui,ZHANG Wanxin.Differential Expression of Glycolysis-related Genes in Patients with Advanced Hepatocellular Carcinoma Treated with PD-1 Inhibitors Screened Based on Biological Information Analysis, and Survival Benefit Model Constructed and Verified[J].Journal of Modern Laboratory Medicine,2023,38(01):34.[doi:10.3969/j.issn.1671-7414.2023.05.007]

备注/Memo

备注/Memo:
基金项目:广西医疗卫生科研课题(2015029)。 作者简介:隆绍平(1978-),男,学士,主管检验师,主要从事医学检验工作及研究,E-mail:652582452@qq.com。 通讯作者:赵世元(1965-),男,博士,主任检验技师,主要从事药物开发研究,E-mail:zhaoshiyuan_1105@163.com。
更新日期/Last Update: 2018-02-07